The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia
| Autor: | Ferenc Andrasi, Franciska Erdo, Pal Berzsenyi |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Brain Infarction
Male Time Factors Ischemia Tetrazolium Salts AMPA receptor Pharmacology Neuroprotection Brain Ischemia Rats Sprague-Dawley Benzodiazepines Mice chemistry.chemical_compound medicine.artery Laser-Doppler Flowmetry Animals Medicine Receptors AMPA Stroke Talampanel Rose Bengal Dose-Response Relationship Drug business.industry General Neuroscience Glutamate receptor Antagonist Infarction Middle Cerebral Artery medicine.disease Rats Mice Inbred C57BL Disease Models Animal Neuroprotective Agents chemistry Anesthesia Middle cerebral artery business |
| Zdroj: | Brain Research Bulletin. 66:43-49 |
| ISSN: | 0361-9230 |
| Popis: | Cerebroprotection after administration of glutamate receptor antagonists has been well documented. The present study is intended to determine whether the non-competitive alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid (AMPA) receptor antagonist talampanel, known as antiepileptic drug, has neuroprotective effects in stroke models in rodents. The infarct size was measured in three models of stroke by 2,3,5-triphenyltetrazolium chloride staining. Therapeutic time window was also examined in rats subjected to 1h middle cerebral artery occlusion. The degree of neuroprotection was tested in mice, using 1.5, 2 h or permanent middle cerebral artery occlusions. Effect on photochemically induced thrombosis was investigated in rats applying 30 min time window after brain irradiation. Talampanel reduced the infarct size by 47.3% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect